ATE439380T1 - Methoden zur herstellung humaner monoklonaler antikörper - Google Patents

Methoden zur herstellung humaner monoklonaler antikörper

Info

Publication number
ATE439380T1
ATE439380T1 AT01903344T AT01903344T ATE439380T1 AT E439380 T1 ATE439380 T1 AT E439380T1 AT 01903344 T AT01903344 T AT 01903344T AT 01903344 T AT01903344 T AT 01903344T AT E439380 T1 ATE439380 T1 AT E439380T1
Authority
AT
Austria
Prior art keywords
monoclonal antibodies
methods
human monoclonal
producing human
cell type
Prior art date
Application number
AT01903344T
Other languages
English (en)
Inventor
Ronghao Li
Original Assignee
Macrogenics West Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics West Inc filed Critical Macrogenics West Inc
Application granted granted Critical
Publication of ATE439380T1 publication Critical patent/ATE439380T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT01903344T 2000-01-26 2001-01-26 Methoden zur herstellung humaner monoklonaler antikörper ATE439380T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/491,894 US6541225B1 (en) 2000-01-26 2000-01-26 Methods and compositions for generating human monoclonal antibodies
PCT/US2001/002588 WO2001055216A1 (en) 2000-01-26 2001-01-26 Methods and compositions for generating human monoclonal antibodies

Publications (1)

Publication Number Publication Date
ATE439380T1 true ATE439380T1 (de) 2009-08-15

Family

ID=23954109

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01903344T ATE439380T1 (de) 2000-01-26 2001-01-26 Methoden zur herstellung humaner monoklonaler antikörper

Country Status (10)

Country Link
US (3) US6541225B1 (de)
EP (1) EP1255780B1 (de)
JP (1) JP4790959B2 (de)
KR (1) KR20020073185A (de)
CN (1) CN100491397C (de)
AT (1) ATE439380T1 (de)
AU (2) AU2001231172B2 (de)
CA (1) CA2398284A1 (de)
DE (1) DE60139542D1 (de)
WO (1) WO2001055216A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541225B1 (en) * 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
US6794141B2 (en) * 2000-12-22 2004-09-21 Arcturus Bioscience, Inc. Nucleic acid amplification
US20030096414A1 (en) 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
GB0312481D0 (en) * 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
EP1694278A4 (de) * 2003-12-16 2009-08-12 Ipsen Pharma Glp-1 pharmazeutische zusammensetzungen
US7771999B2 (en) * 2004-04-28 2010-08-10 Vaxdesign Corp. Disease model incorporation into an artificial immune system (AIS)
US8071373B2 (en) 2004-04-28 2011-12-06 Sanofi Pasteur Vaxdesign Corp. Co-culture lymphoid tissue equivalent (LTE) for an artificial immune system (AIS)
US8030070B2 (en) * 2004-04-28 2011-10-04 Sanofi Pasteur Vaxdesign Corp. Artificial lymphoid tissue equivalent
US7855074B2 (en) 2004-04-28 2010-12-21 Vaxdesign Corp. Artificial immune system: methods for making and use
US7785883B2 (en) * 2004-04-28 2010-08-31 Vax Design Corp. Automatable artificial immune system (AIS)
US7709256B2 (en) * 2004-04-28 2010-05-04 Vaxdesign Corp. Disease model incorporation into an artificial immune system (AIS)
US7785806B2 (en) * 2004-04-28 2010-08-31 Vaxdesign Corporation Method for determining the immunogenicity of an antigen
US8298824B2 (en) 2004-04-28 2012-10-30 Sanofi Pasteur Vaxdesign Corporation Methods of evaluating a test agent in a diseased cell model
JP4824025B2 (ja) * 2004-06-07 2011-11-24 マクロジェニックス ウエスト，インコーポレイテッド トランスフェリンレセプター抗体
US20060171952A1 (en) * 2005-02-02 2006-08-03 Mather Jennie P JAM-3 and antibodies that bind thereto
US7572896B2 (en) * 2005-02-03 2009-08-11 Raven Biotechnologies, Inc. Antibodies to oncostatin M receptor
CN101155830B (zh) * 2005-02-04 2014-06-18 雷文生物技术公司 结合epha2的抗体及其使用方法
EP1910513B1 (de) * 2005-07-01 2016-08-10 John Schrader Verfahren zur Isolierung Antikörper-sezernierender Zellen aus dem Blut immunisierter Tiere und Menschen und Erzeugung monoklonaler Antikörper aus diesen Antikörper-sezernierenden Zellen.
WO2007075979A2 (en) 2005-12-21 2007-07-05 Vaxdesign Corporation In vitro germinal centers
US20070178076A1 (en) * 2005-12-21 2007-08-02 Drake Donald Iii Porous membrane device that promotes the differentiation of monocytes into dendritic cells
KR100850416B1 (ko) * 2006-06-21 2008-08-04 남상윤 자가세포 파괴에 의해 야기되는 자가면역질환의 치료를위한 세포치료제 및 그 제조 방법
EP2409715A1 (de) * 2006-06-27 2012-01-25 Sanofi Pasteur VaxDesign Corporation Modelle für die Bewertung von Impfstoffen
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
CA2692689A1 (en) * 2007-07-06 2009-01-15 Vaxdesign Corporation Rapid generation of t cell-independent antibody responses to t cell-dependent antigens
WO2009048661A1 (en) 2007-07-16 2009-04-16 Vaxdesign Corporation Artificial tissue constructs comprising alveolar cells and methods for using the same
AU2008284015B2 (en) 2007-08-03 2014-05-15 Musc Foundation For Research Development Human monoclonal antibodies and methods for producing the same
WO2009054556A1 (en) * 2007-10-24 2009-04-30 Sang Yun Nam Method for preparation of therapeutic b cells against autoimmune diseases which are induced by autoimmune cytotoxicity
US20100248971A1 (en) * 2007-12-03 2010-09-30 Takashi Inagaki Process for antibody production
EP2242836B1 (de) * 2008-01-28 2015-05-20 Thomas Jefferson University Verfahren zur herstellung von hybridzellen zur expression nützlicher antikörper
ES2589912T3 (es) 2008-04-02 2016-11-17 Macrogenics, Inc. Anticuerpos específicos para el complejo BCR y procedimientos de uso de los mismos
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
EP2542256B1 (de) 2010-03-04 2019-05-22 MacroGenics, Inc. Mit b7-h3 reagierende antikörper, immunologisch wirkende fragmente davon und verwendungen davon
SI2400298T1 (sl) * 2010-05-28 2013-11-29 F. Hoffmann-La Roche Ag Postopek kultivacije posamezne B-celice in izdelava specifičnih protiteles
TWI477603B (zh) * 2011-01-28 2015-03-21 鴻海精密工業股份有限公司 培育基體之製備方法
SG10201805064SA (en) 2011-06-23 2018-07-30 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
RS55775B2 (sr) 2011-06-23 2022-10-31 Ablynx Nv Tehnike za predviđanje, otkrivanje i smanjenje nespecifične proteinske interferencije u testovima koji uključuju pojedinačne varijabilne domene imunoglobulina
EP2724157B1 (de) * 2011-06-27 2017-03-08 Valneva Screening-verfahren für zellen
CN102321720B (zh) * 2011-07-28 2014-09-03 万晓春 一种混合细胞培养生产纯人源单克隆抗体的方法
EP2914629A1 (de) 2012-11-05 2015-09-09 MAB Discovery GmbH Verfahren zur herstellung multispezifischer antikörper
EP2727941A1 (de) 2012-11-05 2014-05-07 MAB Discovery GmbH Verfahren zur Herstellung multispezifischer Antikörper
EP2727942A1 (de) 2012-11-05 2014-05-07 MAB Discovery GmbH Bispezifische Antikörper gegen menschliche EGFR, HER2 und HER3
EP2727943A1 (de) 2012-11-05 2014-05-07 MAB Discovery GmbH Trispezifische Antikörper gegen menschliche EGFR, HER2 und HER3
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
JP7114460B2 (ja) 2015-06-26 2022-08-08 サノフィ・バイオテクノロジー モノクローナル抗ＩＬ－１ＲＡｃＰ抗体
US10222373B2 (en) 2016-02-29 2019-03-05 Rarecyte, Inc. Method to identify antigen-specific immune cells
US9442113B1 (en) 2016-02-29 2016-09-13 Rarecyte, Inc. Method to identify antigen-specific immune cells for therapeutic development
US9395367B1 (en) 2016-02-29 2016-07-19 Rarecyte, Inc. Method to identify antigen-specific B cells for antibody development
GEP20227398B (en) 2016-04-15 2022-07-25 Macrogenics Inc Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof
EP3241845A1 (de) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanisierte anti-il-1r3-antikörper
EP3401332A1 (de) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antikörper zur verwendung bei entzündungskrankheiten
TW202016144A (zh) * 2018-06-21 2020-05-01 日商第一三共股份有限公司 包括cd3抗原結合片段之組成物及其用途
AR130550A1 (es) 2022-09-21 2024-12-18 Sanofi Biotechnology Anticuerpo anti-il-1r3 humanizado y métodos de uso

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4643971A (en) * 1983-03-11 1987-02-17 Sloan-Kettering Institute Monoclonal antibodies to human bladder and ureter cancers and method
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
EP0218158A3 (de) 1985-09-30 1988-12-07 Asahi Kasei Kogyo Kabushiki Kaisha Menschlicher monoklonaler Antikörper, B-Zell-Linie für die Herstellung dieses Antikörpers und Verfahren zur Herstellung dieser B-Zell-Linie und Antikörper.
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DK0488470T3 (da) * 1990-11-26 1997-12-22 Akzo Nobel Nv Fremgangsmåde til fremstilling af antistoffer
US5256542A (en) * 1992-03-09 1993-10-26 Tanox Biosystems, Inc. Selecting low frequency antigen-specific single B lymphocytes with correction for background noise
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
AU6396494A (en) 1992-11-16 1994-06-08 Cancer Research Fund Of Contra Costa Peptides and anti-sense peptides with broad neoplastic specificity
GB9526131D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US5882644A (en) * 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
IL122233A (en) * 1996-12-06 2001-04-30 Akzo Nobel Nv Method of generating monoclonal antibodies to cell wall and pharmaceutical preparations and diagnostic agents containing them
EP0983303B1 (de) * 1997-05-21 2006-03-08 Biovation Limited Verfahren zur herstellung von nicht-immunogenen proteinen
US6004528A (en) * 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
US6541225B1 (en) 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies

Also Published As

Publication number Publication date
US20030109006A1 (en) 2003-06-12
EP1255780B1 (de) 2009-08-12
JP4790959B2 (ja) 2011-10-12
CA2398284A1 (en) 2001-08-02
CN1420893A (zh) 2003-05-28
AU3117201A (en) 2001-08-07
HK1050695A1 (en) 2003-07-04
US6541225B1 (en) 2003-04-01
JP2003531578A (ja) 2003-10-28
KR20020073185A (ko) 2002-09-19
AU2001231172B2 (en) 2006-05-25
EP1255780A1 (de) 2002-11-13
DE60139542D1 (de) 2009-09-24
US20060252124A1 (en) 2006-11-09
WO2001055216A1 (en) 2001-08-02
US8137668B2 (en) 2012-03-20
CN100491397C (zh) 2009-05-27

Similar Documents

Publication Publication Date Title
ATE439380T1 (de) Methoden zur herstellung humaner monoklonaler antikörper
CY1113153T1 (el) ΙL-1β ΔΕΣΜΕΥΤΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ΚΑΙ ΘΡΑΥΣΜΑΤΑ ΑΥΤΩΝ
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
SI1629011T1 (sl) Humane molekule za vezavo anti hu cd
DK1414858T3 (da) Kamelid-enkeltkæde-VHH-antistoffer, fremgangsmåde til fremstilling heraf i et pattedyr samt anvendelser heraf
ATE459651T1 (de) Antigenbindende domäne aus fisch
WO2003034903A3 (en) Psma antibodies and protein multimers
DE69932813D1 (de) Nukleinsäurebindungsproteine
WO2005028625A3 (en) Consensus/ancestral immunogens
WO2002083738A1 (fr) Anticorps trispecifique monocatenaire cyclique
ATE348633T1 (de) Verfahren zur verstärkung einer immunantwort von nukleinsäureimpfungen
WO2002033116A3 (en) Nucleic acid ligands to the prostate specific membrane antigen
DE60217708D1 (de) Verfahren, um ein elastisches verbundmaterial herzustellen
BRPI0513135A (pt) bibliotecas de polinucleotìdeos, método de produção das mesmas, método de identificação de um polinucleotìdeo, região de ligação, meio adequado para uso em um, dispositivo eletrÈnico e dispositivo
WO2001077291A3 (en) Polynucleotides encoding novel secreted proteins
WO2002063010A3 (en) Method of producing recombinant antibodies against tumors
ATE370163T1 (de) Antikörper zur isolierung und/oder identifizierung mesenchymaler stammzellen und verfahren zur isolierung und/oder identifizierung mesenchymaler stammzellen
ATE358172T1 (de) Verfahren zur herstellung von olefinen.
ATE296816T1 (de) Verfahren zur herstellung von ethern, vorzugsweise von thf
DE69934250D1 (de) Zusammensetzungen und verfahren zur herstellung monoklonaler antikörper, repräsentativ für einen spezifischen zelltyp
DE69840326D1 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
ATE391115T1 (de) Verfahren zur herstellung von diketenacetalen
WO2001077288A3 (en) Polynucleotides encoding novel secreted proteins
WO2005049652A3 (en) Methods of generating antibody diversity in vitro
WO2004087759A3 (en) Method and compositions for conversion of antibody activity

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties